Application of phloretin in preparation of aeromonas hydrophila infection resisting medicine

By inhibiting the activity of disulfide bond reductase of Aeromonas hydrophila, rhizotocarbazin is used as the active ingredient of anti-Aeromonas hydrophila infection drug, the drug resistance problem is solved and significantly improved Aeromonas hydrophila crucian carp The survival rate of the infection model and reduces the risk of drug residues, achieving effective treatment of drug-resistant bacteria.

CN118903075APending Publication Date: 2024-11-08YANGTZE RIVER FISHERIES RES INST CHINESE ACAD OF FISHERY SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411329275.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing anti-Aeromonas hydrophilic drugs rely on chemical antibacterial drugs, which leads to the production of drug-resistant bacteria, affects the therapeutic effect, and has potential risks of drug residues on the ecological environment and human health. It is urgent to develop new anti-drug-resistant hydrophilic gas. Monasa infection drugs.

Method used

Using rhizodocarcin as the active ingredient, by inhibiting the activity of Aeromonas hydrophila disulfide reductase, it significantly inhibits its pathogenicity, and provides a drug and feed to prevent Aeromonas hydrophila infection, and administers dosage Not less than 25 mg/kg to avoid direct inhibition of pathogen growth to reduce drug resistance.

Benefits of technology

Rhizotocin effectively inhibits the activity of disulfide bond reductase at low concentrations, significantly improves the survival rate of Aeromonas hydrophila infection model, and still has a good therapeutic effect on drug-resistant bacteria, which is safe High in nature and low risk of drug residues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903075A_ABST
    Figure CN118903075A_ABST
Patent Text Reader

Abstract

The invention is applicable to the technical field of medicine and aquaculture, and provides application of phloretin in preparation of aeromonas hydrophila infection resistant drugs, phloretin almost has no bacteriostatic action on aeromonas hydrophila, but can directly inhibit the activity of disulfide bond reductase of aeromonas hydrophila at a lower concentration, so that phloretin can be used for preparing drugs for resisting aeromonas hydrophila infection. The phloretin has a remarkable inhibition effect on cytotoxicity caused by aeromonas hydrophila, and the survival rate of a crucian carp aeromonas hydrophila infection model can be remarkably improved through phloretin treatment. Besides, the phloretin is derived from pericarp or root bark of fruits such as apples and pears, is a natural compound, has biological functions of oxidation resistance, inflammation resistance, tumor resistance, immunosuppression and the like, has no toxic or side effect on animals, human and ecological environment, and is relatively high in safety and relatively low in drug residue risk; the method can be widely used for preparing drugs and feed additives for resisting aeromonas hydrophila infection of aquaculture animals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine and aquaculture, and in particular relates to application of phloretin in preparing a drug for resisting Aeromonas hydrophila infection. Background Art

[0002] Phloretin is a naturally derived flavonoid polyphenol compound that is mainly found in a variety of plants such as apples and pears. It has antioxidant, antibacterial, anti-cancer and anti-inflammatory functions.

[0003] Aeromonas hydrophila is a common pathogen in freshwater aquaculture. It can cause disease in most freshwater farmed fish and can also infect crayfish, bullfrogs, etc., which poses a great threat to the healthy development of the aquaculture industry. In addition, Aeromonas hydrophila is also a common pathogen of humans, animals and fish, often causing diarrhea, sepsis, etc. in humans. The prevention and control of Aeromonas hydrophila disease in farmed fish mainly relies on chemical antibacterial drugs. Long-term irrational use has led to the production of drug-resistant bacteria, which seriously affects the treatment effect. In addition, drug residues in the environment and fish bodies pose potential risks to the ecological environment and human health. Therefore, there is an urgent need to develop new drugs to resist drug-resistant Aeromonas hydrophila infections for the prevention and control of fish diseases caused by drug-resistant bacteria. Summary of the invention

[0004] The purpose of the present invention is to provide the use of phloretin in the preparation of drugs for resisting Aeromonas hydrophila infection, aiming to solve the problems raised in the background technology.

[0005] In view of the above problems, the present invention is achieved by using phloretin in the preparation of drugs for resisting Aeromonas hydrophila infection.

[0006] Preferably, the phloretin is used to prevent or treat aquaculture animals from being infected with Aeromonas hydrophila.

[0007] Preferably, the phloretin is used to inhibit the activity of disulfide reductase of Aeromonas hydrophila.

[0008] Preferably, the dosage of phloretin is not less than 25 mg / kg.

[0009] Another object of the present invention is to provide a drug for preventing Aeromonas hydrophila infection, comprising a pharmaceutically acceptable carrier and phloretin as an active ingredient.

[0010] Preferably, the dosage of phloretin is not less than 25 mg / kg.

[0011] Another object of the present invention is to provide a feed for resisting Aeromonas hydrophila infection, comprising a base material and phloretin as an additive.

[0012] Preferably, the feeding amount of phloretin is not less than 25 mg / kg.

[0013] The present invention provides an application of phloretin in resisting Aeromonas hydrophila infection in aquaculture animals, wherein phloretin has almost no antibacterial effect on Aeromonas hydrophila, but can directly inhibit the activity of disulfide bond reductase of Aeromonas hydrophila at a relatively low concentration, and has a significant inhibitory effect on the cytotoxicity caused by Aeromonas hydrophila, and phloretin treatment can significantly improve the survival rate of a crucian carp Aeromonas hydrophila infection model. Since the anti-infection effect of phloretin does not directly inhibit the growth of pathogens, it will not cause selective pressure on pathogens and is not easy to produce drug resistance. In addition, since the effect of the drug is not antibacterial, it still has a good therapeutic effect on drug-resistant bacteria.

[0014] Phloretin is a natural compound derived from the peel or root bark of fruits such as apples and pears. It has biological functions such as antioxidant, anti-inflammatory, anti-tumor and immunosuppression. It has no toxic side effects on animals, humans and the ecological environment, is highly safe, and has a low risk of drug residues. It can be widely used in the preparation of drugs and feed additives to prevent Aeromonas hydrophila infection in aquaculture animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is the growth curve of co-culture of phloretin and Aeromonas hydrophila; Figure 2 This is the result diagram of the effect of phloretin on the disulfide reductase activity of Aeromonas hydrophila; Figure 3 This is the result diagram of the effect of phloretin on the damage of A549 cells induced by Aeromonas hydrophila; Figure 4 This is a graph showing the therapeutic results of phloretin on the Aeromonas hydrophila infection model. DETAILED DESCRIPTION

[0016] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0017] The disulfide reductase of Aeromonas hydrophila is involved in the correct folding of the virulence protein of the pathogen. Studies have found that the pathogenicity of Aeromonas hydrophila in vivo and in vitro is significantly reduced after the loss of disulfide reductase. Therefore, disulfide reductase can be used as a potential target for the study of drugs against Aeromonas hydrophila infection.

[0018] In one embodiment of the present invention, there is provided a use of phloretin in the preparation of a drug for resisting Aeromonas hydrophila infection.

[0019] Specifically, phloretin is used to prevent or treat Aeromonas hydrophila infection in aquaculture animals.

[0020] Furthermore, phloretin was used to inhibit the activity of disulfide reductase of Aeromonas hydrophila.

[0021] In a preferred embodiment of the present invention, the dosage of phloretin is not less than 25 mg / kg.

[0022] In another embodiment of the present invention, a drug for resisting Aeromonas hydrophila infection is provided, comprising a pharmaceutically acceptable carrier and phloretin as an active ingredient; wherein the dosage of phloretin is not less than 25 mg / kg.

[0023] In another embodiment of the present invention, a feed for resisting Aeromonas hydrophila infection is provided, comprising a base material and phloretin as an additive; wherein the feeding amount of phloretin is not less than 25 mg / kg.

[0024] In the embodiments of the present invention, phloretin can be used to resist Aeromonas hydrophila infection in aquaculture animals, and can significantly improve the survival rate of the Aeromonas hydrophila infection model of crucian carp. The application of phloretin and the specific experiments used to verify its therapeutic effect refer to the following embodiments.

[0025] Example 1: Determination of the minimum inhibitory concentration of phloretin on Aeromonas hydrophila. The Aeromonas hydrophila XS-91-4-1 strain involved in the present embodiment is a well-known strain, which is preserved by the Aquatic Animal Pharmacology and Drug Residue Control Technology Laboratory of the Yangtze River Fisheries Research Institute. The minimum inhibitory concentration of phloretin on XS-91-4-1 was determined using the broth microdilution method recommended by CLSI, and the steps are as follows: S1. Dilute the prepared phloretin (Sichuan Weikeqi Biotechnology Co., Ltd., purity > 98%, CAS No. 60-82-2) in a 96-well cell culture plate in series, so that the concentrations in wells 1 to 10 are 512 μg / mL, 256 μg / mL, 128 μg / mL, 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, 2 μg / mL, and 1 μg / mL, respectively; the drug volume in each well is 100 μL; S2. Aseptically inoculate a single colony of the XS-91-4-1 strain into MH medium and culture overnight at 30 °C. Centrifuge the cells and adjust the concentration to 0.5 McFarland turbidity with sterile saline. Then dilute with medium to 1×10 6 CFU / mL, add bacterial solution to a 96-well cell culture plate to a final concentration of 5×10 5CFU / mL, set up negative and positive control groups (negative control group without drug or bacterial solution, positive control group only with bacterial solution without drug), each drug was repeated three times, and the results were observed after culturing in a 28℃ biochemical incubator for 16-18h. The lowest drug concentration without bacterial growth was determined as the minimum inhibitory concentration of the drug. The results showed that Aeromonas hydrophila XS-91-4-1 strain still grew at the highest concentration (256 μg / mL), so it was determined that the minimum inhibitory concentration of phloretin was greater than 256 μg / mL.

[0026] Example 2: Effect of phloretin on the growth of Aeromonas hydrophila. The Aeromonas hydrophila XS-91-4-1 strain involved in the present embodiment is a well-known strain, which is preserved by the Aquatic Animal Pharmacology and Drug Residue Control Technology Laboratory of Yangtze River Fisheries Research Institute. The XS-91-4-1 strain was cultured in BHI liquid medium until the early logarithmic growth period (OD 600nm =0.3, 28 ℃), the cultured bacteria were placed in 6 50 mL conical flasks, 20 mL in each flask, and different concentrations of phloretin (0, 2, 4, 8, 16 μg / mL) were added. The culture was continued at 28 ℃ for 5 h, and the OD of the culture solution was measured every 30 min. 600nm The absorption value of Figure 1 shown. Figure 1 Shown is the growth curve of co-culture of different concentrations of phloretin and Aeromonas hydrophila XS-91-4-1 strain. It can be seen from the figure that phloretin has no effect on the growth of Aeromonas hydrophila when the concentration is 16 μg / mL and below.

[0027] Example 3: The inhibitory effect of phloretin on the activity of recombinant disulfide reductase. The recombinant disulfide reductase involved in the embodiment of the present invention was prepared by the aquatic animal pharmacology and drug residue control technology laboratory of the Yangtze River Fisheries Research Institute through a prokaryotic expression method, and was stored in a -80°C refrigerator for use after purification. The inhibitory effect of phloretin on the activity of disulfide reductase was determined by the insulin reduction method, and the specific steps are as follows: Add 140 µL of reaction buffer to a 96-well cell culture plate, add 20 µL of DsbA protein at a concentration of 0.3 mM, and 20 µL of porcine insulin at a concentration of 20 mM. Then add different concentrations of phloretin to each well, so that the final concentrations in the reaction system are 0, 1, 2, 4, and 8 μg / mL, respectively. Pre-react phloretin and DsbA in the above reaction system for 15 min, and then add 20 µL of 50 mM DTT to each well to start the reaction. Set up 3 parallels for each concentration group, and set up a negative control group (DsbA is replaced by 20 µL of reaction buffer). Measure the absorbance value at 650 nm once at the beginning of the reaction (the blank control group is marked as A 起始FThe experimental group with added drug is marked as A 起始D,),反应120 min后再测定一次650 nm处的吸收值,空白对照组标记为A反应后F,添加药物的试验组标记为A反应后D The relative activity calculation formula of disulfide bond reductase is: Relative activity (%) = (A 反应后D -A 起始D) / (A反应后F -A 起始F)×100%; The above test results are as follows Figure 2 As shown in the figure, it can be seen that with the increase of phloretin concentration, the relative activity of disulfide bond reductase decreased in a dose-dependent manner, and the phloretin concentration in the range of 1-8 μg / mL can significantly inhibit the activity of disulfide bond reductase.

[0028] Example 4: Phloretin reduces cell damage caused by Aeromonas hydrophila. The Aeromonas hydrophila and A549 cells involved in the present embodiment were preserved by the Yangtze River Fisheries Research Institute. A549 cells were cultured in an incubator containing 5% carbon dioxide. The culture medium was DMEM supplemented with 10% fetal bovine serum and penicillin-streptomycin. During the experiment, the cells were cultured at 1.5×10 5 The concentration of 0.1 μg / mL was plated on a 96-well cell culture plate and cultured overnight in a 37°C CO2 incubator. Aeromonas hydrophila was co-cultured with different concentrations of phloretin (0, 1, 2, 4, and 8 μg / mL) until OD 600nm =1.5, and then the cells were collected, washed with PBS and added to the cell culture plate, with an infection ratio of 1:50. After infection, the cell culture plate was placed in a 37 ℃ carbon dioxide incubator for 2 hours, and then the supernatant was centrifuged and the lactate dehydrogenase (LDH) release kit was used to determine the LDH release amount of different treatment groups. Figure 3 As shown in the figure, the LDH release rate of A549 cells decreased in a dose-dependent manner with the increase of phloretin concentration. The above results indicate that phloretin has a significant protective effect against cell damage induced by Aeromonas hydrophila.

[0029] Example 5: The therapeutic effect of phloretin on the Aeromonas hydrophila infection model of crucian carp. The Aeromonas hydrophila XS-91-4-1 strain involved in the embodiment of the present invention is an existing well-known strain, which is preserved by the Aquatic Animal Pharmacology and Drug Residue Control Technology Laboratory of the Yangtze River Fisheries Research Institute. The experiment was carried out in a 100cm×50cm×60cm glass aquarium, and the water was changed every day and the water temperature was maintained at about 28±2°C. An artificial infection model was established by intraperitoneal injection of Aeromonas hydrophila XS-91-4-1 strain into healthy crucian carp weighing about 100 g after anesthesia. Starting 2 hours after infection, the infected crucian carp was orally administered with a dose of 25 mg / kg of phloretin, once every 12 hours for 3 consecutive days. The positive control group was orally administered with PBS after infection as a control. 30 crucian carps were used in each test group, and the mortality was recorded immediately after infection. The above test results are shown in the figure. Figure 4As shown. The results showed that the mortality rate of crucian carp artificially infected with Aeromonas hydrophila reached 86.67% within 8 days; 46.67% of crucian carp treated with 25 mg / kg phloretin died; analysis showed that the survival rate of the phloretin treatment group was significantly higher than that of the positive control group. The above studies show that crucian carp can be treated with 25 mg / kg phloretin when infected with Aeromonas hydrophila, and the drug can achieve good therapeutic effects.

[0030] The minimum inhibitory concentration of phloretin against Aeromonas hydrophila was verified by experiments to be greater than 256 μg / mL; through the growth curve test, it was found that phloretin had no effect on the growth of Aeromonas hydrophila at a concentration of 1-8 μg / mL. However, the insulin reduction test showed that phloretin concentrations of 1-8 μg / mL could significantly reduce the activity of disulfide reductase. In addition, phloretin at 1-8 μg / mL had a significant protective effect on cell damage caused by Aeromonas hydrophila. The above results suggest that phloretin can inhibit the pathogenicity of Aeromonas hydrophila by inhibiting the activity of disulfide reductase. Based on the above findings, this experiment established an Aeromonas hydrophila infection model in crucian carp, and found that oral administration of 25 mg / kg phloretin, once every 12 hours for 3 consecutive days, could significantly increase the survival rate of infected crucian carp, and its survival rate could reach 53.33%, while the survival rate of the positive control group was only 13.33%. The above studies show that phloretin can be used as a fishery drug to treat Aeromonas hydrophila infections in aquaculture animals.

[0031] In summary, Aeromonas hydrophila is a conditional pathogen that causes diseases in aquatic animals and humans, especially serious harm to freshwater farmed fish, often causing high morbidity and mortality. Antibiotics were once the main means of treating Aeromonas hydrophila disease in farmed fish, but the development of drug resistance and the residues of drugs in animal edible tissues limit their application. In recent years, studies have found that the disulfide reductase of Aeromonas hydrophila is closely related to the formation of correct disulfide bonds with its various virulence proteins, and the pathogenicity of disulfide reductase-deficient strains in vivo and in vitro is significantly reduced, which can be used as a potential target for studying drugs against Aeromonas hydrophila infection. It was found through Examples 1 and 2 that phloretin had almost no antibacterial effect on Aeromonas hydrophila XS-91-4-1 under the experimental conditions of the present invention. It was found through Example 3 that phloretin had a significant inhibitory effect on the activity of the recombinant protein of disulfide reductase of Aeromonas hydrophila, suggesting that it may have the effect of resisting Aeromonas hydrophila infection. Therefore, the protective effect of phloretin on cultured cells and animal infection models was further studied through Examples 4 and 5. The results showed that phloretin has a protective effect on cell damage induced by Aeromonas hydrophila in a dose-dependent manner. Phloretin has a significant protective effect on the infection model of Aeromonas hydrophila in crucian carp. The above examples show that phloretin can reduce its in vivo and in vitro pathogenicity by directly inhibiting the activity of disulfide reductase at a concentration that does not inhibit the growth of Aeromonas hydrophila. Since the anti-infection concentration of phloretin is much lower than its minimum inhibitory concentration, it is not easy to induce Aeromonas hydrophila to produce drug resistance.

[0032] In addition, Aeromonas hydrophila has a wide range of hosts and can infect a variety of freshwater aquaculture organisms such as fish, frogs, and shrimps. Disulfide bond reductase is widely present in pathogenic strains. It can be inferred that phloretin has a therapeutic effect on infections caused by Aeromonas hydrophila.

[0033] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Application of phloretin in the preparation of drugs for anti-Aeromonas hydrophila infection.

2. The use according to claim 1, characterized in that: The phloretin is used for preventing or treating aquaculture animals from being infected with Aeromonas hydrophila.

3. The use according to claim 1, characterized in that: The phloretin is used for inhibiting the activity of disulfide bond reductase of Aeromonas hydrophila.

4. The use according to any one of claims 1 to 3, characterized in that: The dosage of phloretin is not less than 25 mg / kg.

5. A drug for preventing Aeromonas hydrophila infection, comprising a pharmaceutically acceptable carrier, characterized in that: Also includes phloretin as an active ingredient.

6. The drug for resisting Aeromonas hydrophila infection according to claim 5, characterized in that: The dosage of phloretin is not less than 25 mg / kg.

7. A feed resistant to infection by Aeromonas hydrophila, comprising a base material, characterized in that: Phloretin was also included as an additive.

8. The feed resistant to Aeromonas hydrophila infection according to claim 7, characterized in that: The feeding amount of phloretin is not less than 25 mg / kg.

Citation Information

Patent Citations

  • Water-soluble phloretin solid dispersion and preparation method thereof

    CN105362229A

  • Preparation and application of phloretin-loaded soybean lecithin-chitosan nanoparticles for preventing diabetes

    CN114209663A

  • Composition comprising stilbenes suitable for enhancing aquaculture productivity

    WO2018206573A1